Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.

More about this publication

Nature cancer
  • Volume 4
  • Issue nr. 9
  • Pages 1395
  • Publication date 01-09-2023

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.